Patents by Inventor Peter Francis Daniel

Peter Francis Daniel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE
    Publication number: 20240091303
    Abstract: Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I)-(XI), and methods of determining the efficacy of TRPC5 inhibitor therapies using the same.
    Type: Application
    Filed: October 5, 2020
    Publication date: March 21, 2024
    Inventors: John Francis Reilly, Yossi Dagon, Hari Raghu, Marie-Francoise Yveline Coeffet-Le Gal, Matthew H. Daniels, Maolin Yu, Mark W. Ledeboer, Jean-Christophe P. Harmange, Peter H. Mundel
  • Compositions and methods for treating Gaucher disease
    Patent number: 11571466
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: February 7, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • High mannose proteins and methods of making high mannose proteins
    Patent number: 10041137
    Abstract: The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB), and allowing production of GCB having a precursor oligosaccharide under conditions which prevent the removal of at least one mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB, to thereby produce an hmGCB preparation. Preferably, the condition which prevents the removal of at least one mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB preparation and methods of using an hmGCB preparation.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: August 7, 2018
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Carol M. Kinoshita, Prashant Mishra, Marianne Borowski, Peter Francis Daniel
  • COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE
    Publication number: 20140242061
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE
    Publication number: 20110027254
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Application
    Filed: July 28, 2010
    Publication date: February 3, 2011
    Inventors: Peter Francis DANIEL, Michael W. Heartlein
  • High mannose proteins and methods of making high mannose proteins
    Patent number: 7138262
    Abstract: The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB), and allowing production of GCB having a precursor oligosaccharide under conditions which prevent the removal of at least one mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB, to thereby produce an hmGCB preparation. Preferably, the condition which prevents the removal of at least one mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB preparation and methods of using an hmGCB preparation.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: November 21, 2006
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Peter Francis Daniel